Vanda Pharmaceuticals (VNDA) Receivables (2016 - 2025)
Historic Receivables for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $50.5 million.
- Vanda Pharmaceuticals' Receivables rose 1821.63% to $50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.5 million, marking a year-over-year increase of 1821.63%. This contributed to the annual value of $47.1 million for FY2024, which is 3790.37% up from last year.
- Vanda Pharmaceuticals' Receivables amounted to $50.5 million in Q3 2025, which was up 1821.63% from $45.0 million recorded in Q2 2025.
- In the past 5 years, Vanda Pharmaceuticals' Receivables registered a high of $50.5 million during Q3 2025, and its lowest value of $24.5 million during Q1 2023.
- In the last 5 years, Vanda Pharmaceuticals' Receivables had a median value of $34.2 million in 2023 and averaged $36.6 million.
- Per our database at Business Quant, Vanda Pharmaceuticals' Receivables skyrocketed by 5085.21% in 2021 and then plummeted by 2926.55% in 2022.
- Quarter analysis of 5 years shows Vanda Pharmaceuticals' Receivables stood at $32.5 million in 2021, then grew by 3.22% to $33.5 million in 2022, then increased by 1.92% to $34.2 million in 2023, then skyrocketed by 37.9% to $47.1 million in 2024, then rose by 7.3% to $50.5 million in 2025.
- Its Receivables stands at $50.5 million for Q3 2025, versus $45.0 million for Q2 2025 and $44.6 million for Q1 2025.